259 related articles for article (PubMed ID: 27158798)
1. Infliximab therapy balances regulatory T cells, tumour necrosis factor receptor 2 (TNFR2) expression and soluble TNFR2 in sarcoidosis.
Verwoerd A; Hijdra D; Vorselaars AD; Crommelin HA; van Moorsel CH; Grutters JC; Claessen AM
Clin Exp Immunol; 2016 Aug; 185(2):263-70. PubMed ID: 27158798
[TBL] [Abstract][Full Text] [Related]
2. Increased Regulatory T Cells in Peripheral Blood of Acute Myeloid Leukemia Patients Rely on Tumor Necrosis Factor (TNF)-α-TNF Receptor-2 Pathway.
Wang M; Zhang C; Tian T; Zhang T; Wang R; Han F; Zhong C; Hua M; Ma D
Front Immunol; 2018; 9():1274. PubMed ID: 29922294
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of high levels of soluble tumour necrosis factor-α receptor-2 produced by alternative splicing in rheumatoid arthritis: a longitudinal prospective cohort study.
Cañete JD; Albaladejo C; Hernández MV; Laínez B; Pinto JA; Ramírez J; López-Armada MJ; Rodríguez-Cros JR; Engel P; Blanco FJ; Sanmartí R
Rheumatology (Oxford); 2011 Apr; 50(4):721-8. PubMed ID: 21134963
[TBL] [Abstract][Full Text] [Related]
4. The Significance of Tumor Necrosis Factor Receptor Type II in CD8
Ye LL; Wei XS; Zhang M; Niu YR; Zhou Q
Front Immunol; 2018; 9():583. PubMed ID: 29623079
[TBL] [Abstract][Full Text] [Related]
5. Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients.
Govindaraj C; Tan P; Walker P; Wei A; Spencer A; Plebanski M
Clin Cancer Res; 2014 Feb; 20(3):724-35. PubMed ID: 24297862
[TBL] [Abstract][Full Text] [Related]
6. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.
Ebert EC; Das KM; Mehta V; Rezac C
Clin Exp Immunol; 2008 Dec; 154(3):325-31. PubMed ID: 18826498
[TBL] [Abstract][Full Text] [Related]
7. Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn's disease.
Schmitt H; Billmeier U; Dieterich W; Rath T; Sonnewald S; Reid S; Hirschmann S; Hildner K; Waldner MJ; Mudter J; Hartmann A; Grützmann R; Neufert C; Münster T; Neurath MF; Atreya R
Gut; 2019 May; 68(5):814-828. PubMed ID: 29848778
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells.
Kampan NC; Madondo MT; McNally OM; Stephens AN; Quinn MA; Plebanski M
Front Immunol; 2017; 8():1482. PubMed ID: 29163543
[TBL] [Abstract][Full Text] [Related]
9. Regulatory T cells with CD62L or TNFR2 expression in young type 1 diabetic patients: relation to inflammation, glycemic control and micro-vascular complications.
El-Samahy MH; Adly AA; Ismail EA; Salah NY
J Diabetes Complications; 2015; 29(1):120-6. PubMed ID: 25113439
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.
Govindaraj C; Madondo M; Kong YY; Tan P; Wei A; Plebanski M
Am J Hematol; 2014 Aug; 89(8):795-802. PubMed ID: 24757092
[TBL] [Abstract][Full Text] [Related]
11. The effects of TNF-α/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer.
Qu Y; Wang X; Bai S; Niu L; Zhao G; Yao Y; Li B; Li H
Int J Cancer; 2022 Apr; 150(8):1373-1391. PubMed ID: 34766338
[TBL] [Abstract][Full Text] [Related]
12. TNF-α: a treatment target or cause of sarcoidosis?
Amber KT; Bloom R; Mrowietz U; Hertl M
J Eur Acad Dermatol Venereol; 2015 Nov; 29(11):2104-11. PubMed ID: 26419478
[TBL] [Abstract][Full Text] [Related]
13. Changes in lung immune cells related to clinical outcome during treatment with infliximab for sarcoidosis.
Kullberg S; Rivera NV; Abo Al Hayja M; Grunewald J; Eklund A
Clin Exp Immunol; 2020 Jul; 201(1):85-93. PubMed ID: 32275772
[TBL] [Abstract][Full Text] [Related]
14. Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients.
Yan F; Du R; Wei F; Zhao H; Yu J; Wang C; Zhan Z; Ding T; Ren X; Chen X; Li H
Cancer Immunol Immunother; 2015 Nov; 64(11):1475-85. PubMed ID: 26280204
[TBL] [Abstract][Full Text] [Related]
15. An alternative spliced variant of circulating soluble tumor necrosis factor-alpha receptor-2 is paradoxically associated with insulin action.
Fernández-Real JM; Straczkowski M; Lainez B; Chacón MR; Kowalska I; López-Bermejo A; García-España A; Nikolajuk A; Kinalska I; Ricart W
Eur J Endocrinol; 2006 May; 154(5):723-30. PubMed ID: 16645020
[TBL] [Abstract][Full Text] [Related]
16. Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents.
Zou H; Li R; Hu H; Hu Y; Chen X
Front Immunol; 2018; 9():594. PubMed ID: 29632537
[TBL] [Abstract][Full Text] [Related]
17. An immunocytokine consisting of a TNFR2 agonist and TNFR2 scFv enhances the expansion of regulatory T cells through TNFR2 clustering.
Inoue M; Tsuji Y; Kashiwada A; Yokoyama A; Iwata A; Abe Y; Kamada H; Tsunoda SI
Biochem Biophys Res Commun; 2024 Feb; 697():149498. PubMed ID: 38262291
[TBL] [Abstract][Full Text] [Related]
18. TNF activates a NF-kappaB-regulated cellular program in human CD45RA- regulatory T cells that modulates their suppressive function.
Nagar M; Jacob-Hirsch J; Vernitsky H; Berkun Y; Ben-Horin S; Amariglio N; Bank I; Kloog Y; Rechavi G; Goldstein I
J Immunol; 2010 Apr; 184(7):3570-81. PubMed ID: 20181891
[TBL] [Abstract][Full Text] [Related]
19. Distinct immune modulatory roles of regulatory T cells in gut versus joint inflammation in TNF-driven spondyloarthritis.
Venken K; Jarlborg M; Decruy T; Mortier C; Vlieghe C; Gilis E; De Craemer AS; Coudenys J; Cambré I; Fleury D; Klimowicz A; Van den Bosch F; Hoorens A; Lobaton T; de Roock S; Sparwasser T; Nabozny G; Jacques P; Elewaut D
Ann Rheum Dis; 2023 Aug; 82(8):1076-1090. PubMed ID: 37197892
[TBL] [Abstract][Full Text] [Related]
20. Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment.
Govindaraj C; Scalzo-Inguanti K; Madondo M; Hallo J; Flanagan K; Quinn M; Plebanski M
Clin Immunol; 2013 Oct; 149(1):97-110. PubMed ID: 23948613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
